BRPI0514274A - vìrus de varìola aviária recombinante e composição farmacêutica para induzir uma resposta imune celular especìfica contra o vhc - Google Patents

vìrus de varìola aviária recombinante e composição farmacêutica para induzir uma resposta imune celular especìfica contra o vhc

Info

Publication number
BRPI0514274A
BRPI0514274A BRPI0514274-1A BRPI0514274A BRPI0514274A BR PI0514274 A BRPI0514274 A BR PI0514274A BR PI0514274 A BRPI0514274 A BR PI0514274A BR PI0514274 A BRPI0514274 A BR PI0514274A
Authority
BR
Brazil
Prior art keywords
immune response
virus
recombinant
pharmaceutical composition
response against
Prior art date
Application number
BRPI0514274-1A
Other languages
English (en)
Inventor
Liz Alvarez-Lajonchere Po Leon
Santiago Due As Carrera
Ivis Guerra Aizpurua
Nelson Acosta Rivero
Alexis Musacchio Lasa
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of BRPI0514274A publication Critical patent/BRPI0514274A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

VìRUS DE VARìOLA AVIáRIA RECOMBINANTE E COMPOSIçãO FARMACêUTICA PARA INDUZIR UMA RESPOSTA IMUNE CELULAR ESPECìFICA CONTRA O VHC Vírus de varíola aviária recombinante para combinações protéicas baseadas em antígenos do vírus da hepatite C e seu uso em composições farmacêuticas capazes de induzir uma resposta imune celular contra o vírus da hepatite O, depois da administração de um número reduzido de doses. As composições farmacêuticas desta invenção são úteis para a prevenção e tratamento de infecções associadas com o vírus da hepatite C em mamíferos.
BRPI0514274-1A 2004-08-11 2005-08-10 vìrus de varìola aviária recombinante e composição farmacêutica para induzir uma resposta imune celular especìfica contra o vhc BRPI0514274A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU20040174A CU23470A1 (es) 2004-08-11 2004-08-11 Vectores vivos recombinantes y su uso en composiciones farmacéuticas contra el virus de la hepatitis c
PCT/CU2005/000004 WO2006015557A1 (es) 2004-08-11 2005-08-10 Vectores vivos recombinantes y su uso en composiciones farmaceuticas contra el virus de l a hepatitis c

Publications (1)

Publication Number Publication Date
BRPI0514274A true BRPI0514274A (pt) 2008-06-10

Family

ID=40262893

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514274-1A BRPI0514274A (pt) 2004-08-11 2005-08-10 vìrus de varìola aviária recombinante e composição farmacêutica para induzir uma resposta imune celular especìfica contra o vhc

Country Status (14)

Country Link
EP (1) EP1787656A1 (pt)
JP (1) JP2008508890A (pt)
KR (1) KR20070040814A (pt)
CN (1) CN101035560A (pt)
AR (1) AR050451A1 (pt)
AU (1) AU2005270612A1 (pt)
BR (1) BRPI0514274A (pt)
CA (1) CA2575293A1 (pt)
CU (1) CU23470A1 (pt)
MX (1) MX2007001749A (pt)
MY (1) MY170516A (pt)
RU (1) RU2353651C2 (pt)
WO (1) WO2006015557A1 (pt)
ZA (1) ZA200701079B (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0575491B1 (en) * 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
ATE290592T1 (de) * 1993-11-04 2005-03-15 Innogenetics Nv Von menschlichen t-zellen immunodominante epitopen des virus der c-hepatitis
CU22642A1 (es) 1996-12-12 2000-12-22 Ct Ingenieria Genetica Biotech Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso
AU6226100A (en) * 1999-07-19 2001-04-24 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
WO2002080648A2 (en) * 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming

Also Published As

Publication number Publication date
MY170516A (en) 2019-08-08
JP2008508890A (ja) 2008-03-27
CU23470A1 (es) 2009-12-17
EP1787656A1 (en) 2007-05-23
MX2007001749A (es) 2007-04-20
WO2006015557A1 (es) 2006-02-16
KR20070040814A (ko) 2007-04-17
CA2575293A1 (en) 2006-02-16
CN101035560A (zh) 2007-09-12
AR050451A1 (es) 2006-10-25
AU2005270612A1 (en) 2006-02-16
RU2353651C2 (ru) 2009-04-27
ZA200701079B (en) 2008-07-30
RU2007108290A (ru) 2008-09-20

Similar Documents

Publication Publication Date Title
Li et al. Interferon-omega: Current status in clinical applications
BRPI0510016A (pt) vetor lentiviral recombinante para expressão de uma proteìna de flaviviridae e aplicações do mesmo como vacina
BRPI0519705A2 (pt) composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo
BRPI0513370A (pt) uso de uma combinação de ciclosporina e interferonas peguilados para tratamento de hepatite c (hcv)
WO2006041866A3 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
BR112017020986A2 (pt) proteínas de ligação recombinantes e seu uso
BRPI0606479A (pt) composições; proteìnas de fusão; polipepitìdeos; e métodos para estimular uma resposta imune em um indivìduo
ECSP066495A (es) Composiciones y metodos para inhibir la infección por virus de síndrome de punto blanco (wssv)
NZ593926A (en) Methods and compositions based on shiga toxin type 2 protein
EA200602137A1 (ru) Гидрогелевые препараты интерферона
CO2022018715A2 (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
BRPI0707779B8 (pt) antígeno isolado, composição de vacina e método para produção de uma proteína antígeno
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
WO2006088481A3 (en) Genetically engineered equine influenza virus and uses thereof
MX2010002557A (es) Interferon alfa 2b modificado por glicol de polietileno, la preparacion y el uso del mismo.
HRP20100473T1 (hr) Imunostimulatorne kombinacije za profilaksu i liječenje hepatitisa c
BRPI0407840B8 (pt) vírus do sarampo recombinante, composição farmacêutica, uso de uma composição farmacêutica, célula bacteriana, método para produzir um vírus recombinante e uso
BR0012919A (pt) Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv
Nodarse-Cuní et al. Cuban interferon alpha-2b. Thirty years as an effective and safe drug
EA200701166A1 (ru) Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин
BR112022026580A2 (pt) Composições e métodos para induzir uma resposta imune contra coronavírus
BRPI0514884A (pt) composição vacinal para gerar resposta imune celular e humoral protetora contra a infecção pelo vìrus de hepatite c
BRPI0514274A (pt) vìrus de varìola aviária recombinante e composição farmacêutica para induzir uma resposta imune celular especìfica contra o vhc
IL177698A0 (en) Fusion proeins comprising modified allergens of the ns-ltps family, use thereof and pharmaceutical compositions comprising the same
ATE336570T1 (de) Pneumovirus ns proteine antagonisieren die interferon (ifn) antwort

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.